Truist Securities Cuts BSX Price Target to $51
Truist Securities has maintained its Buy rating on Boston Scientific, lowering the price target to $51.0, a 15.58% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Truist Securities cut its price target on Boston Scientific Corporation ($BSX) to $51 from $57 on October 14, 2026, and rates the stock "Buy".
Since the rating, $BSX is up 3.2% to date (from the $43 close on Oct 14, 2026).
BSX
Boston Scientific Corporation
Key Points
- On October 14, 2026, Truist Securities reiterated its Buy rating on Boston Scientific (BSX) with a revised price target of $51.0, down from $57.0.
- Truist Securities's $51 price target implies 15.58% upside from Boston Scientific Corporation's ($BSX) current $44.12 share price.
- As of October 16, 2026, Boston Scientific shares were recently trading at $44.12, which is below its 50-day moving average by about 4.5%.
- The average price target among analysts for Boston Scientific is $59.24, with 29 analysts providing opinions on the stock.
Get $BSX trade alerts by text
We text you when insiders, Congress or big funds trade $BSX. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Boston Scientific Corporation alert may contain errors. Disclosures
Truist Securities has reiterated its Buy rating on Boston Scientific Corporation (NYSE: BSX) and adjusted its price target to $51.0 from $57.0 on October 14, 2026. This move highlights Truist's continued confidence in the company's prospects despite the lowered target.
Truist Securities vs. the S&P 500
Hypothetical returns from Truist Securities's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Boston Scientific
Several institutional investors have adjusted their positions in Boston Scientific recently. BlackRock Inc. reduced its holdings by 2,135,425 shares, ending with 129,680,916 shares valued at about $5.76 billion. Vanguard Capital Management LLC added 674,889 shares, bringing its total to 97,087,553 shares worth approximately $4.31 billion. State Street Corporation increased its stake by 2,121,285 shares, totaling 70,111,196 shares valued at around $3.11 billion. Primecap Management Company saw a notable increase, adding 17,991,834 shares for a total of 50,520,914 shares valued at about $2.24 billion. In contrast, FMR, LLC cut its position by 28,526,236 shares, reducing its total to 45,702,845 shares worth roughly $2.03 billion.
Boston Scientific Corporation Stock Up 2.6%
Boston Scientific shares were recently trading at $44.12, which is below its 50-day moving average of $46.18 by about 4.5%. The stock is also well below its 200-day moving average of $59.36 and its 52-week high of $105.65, reflecting a significant decline in its value over the past year.
$BSX price target
Boston Scientific Corporation daily closes and this analyst's $51 target. Not advice.
Recent Earnings
For the trailing twelve months, Boston Scientific reported revenue of approximately $20.99 billion and an earnings per share (EPS) of $2.47. The company's revenue growth year-over-year stands at 7.5%, and it has a net margin of 17.5%. The next earnings report is scheduled for October 28, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
12 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 0.7%. Revenue met estimates.
-
Profit surprise
EBITDA met by 0 percent. Operating income missed by 13 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 12 target cuts.
-
Earnings quality
Gross margin up 6.2 points. Operating margin up 1.4 points. Positive free cash flow.
Earnings Call Summary
Boston Scientific reported first quarter sales of $5.2 billion, up 9.4 percent, and beat on earnings at $0.80 per share. However, management revealed major headwinds in three key franchises. The EP cardiology ablation business, which grew 22 percent this quarter, is now expected to slow to 10 percent full year as competition from Medtronic, J and J, and Abbott pressures U.S. share. WATCHMAN, which grew 19 percent, slowed sharply in February as stand-alone procedures fell even as concomitant adoption grew. Urology nearly flatlined at 1 percent growth due to problems in stone management and sacral neuromodulation. Management said the company lost more market share than expected and hospital capacity constraints are limiting WATCHMAN procedure volume.
Guidance The company cut its full year sales growth guidance from an expected 8 to 10 percent range down to 6.5 to 8 percent. They expect second quarter sales to grow only 5 to 7 percent year over year. The company now guides full year earnings per share to $3.34 to $3.41, still up 9 to 11 percent but well below prior expectations.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Insider Buying and Selling at Boston Scientific Corporation
Boston Scientific's CEO, Michael F. Mahoney, purchased 186,240 shares at an average price of $48.33 on August 3, 2026, totaling about $9.00 million. Director David C. Habiger bought 1,182 shares on August 4, 2026, valued at $56,887, and later acquired 2,100 shares at $47.59 on August 5, 2026, worth approximately $99,937. Director Susan E. Morano also bought 2,040 shares at $49.22 on August 25, 2026, amounting to around $100,408.
Analysts Set New Price Targets
On October 14, 2026, Truist Securities maintained its Buy rating for Boston Scientific with a target of $51.0, down from $57.0. The consensus among analysts is a buy recommendation, with a mean price target of $59.24 based on 29 opinions.
About Boston Scientific
Boston Scientific Corporation develops and markets medical devices for various medical specialties worldwide, including its MedSurg and Cardiovascular segments. The company's innovative technologies aim to improve patient outcomes and enhance healthcare delivery.
Bottom Line
Investors should watch for Boston Scientific's upcoming earnings report on October 28, 2026, as well as any further updates from analysts regarding their ratings and price targets.
Related Filing Alerts
Source: Truist Securities's rating change on $BSX (Oct 14, 2026). Written by software, not financial advice. How we make alerts